MBX Biosciences, Inc. (NASDAQ:MBX) Short Interest Down 40.0% in January

by · The Cerbat Gem

MBX Biosciences, Inc. (NASDAQ:MBX – Get Free Report) was the target of a significant decline in short interest in January. As of January 15th, there was short interest totaling 2,307,824 shares, a decline of 40.0% from the December 31st total of 3,843,943 shares. Based on an average trading volume of 800,131 shares, the short-interest ratio is currently 2.9 days. Approximately 5.1% of the company’s stock are short sold. Approximately 5.1% of the company’s stock are short sold. Based on an average trading volume of 800,131 shares, the short-interest ratio is currently 2.9 days.

Institutional Trading of MBX Biosciences

Several large investors have recently made changes to their positions in MBX. Russell Investments Group Ltd. lifted its position in MBX Biosciences by 4,131.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock valued at $26,000 after acquiring an additional 1,446 shares in the last quarter. FNY Investment Advisers LLC bought a new position in MBX Biosciences during the third quarter valued at about $27,000. GF Fund Management CO. LTD. bought a new position in shares of MBX Biosciences during the 4th quarter valued at approximately $28,000. BNP Paribas Financial Markets increased its position in MBX Biosciences by 117.9% in the third quarter. BNP Paribas Financial Markets now owns 2,896 shares of the company’s stock worth $51,000 after buying an additional 1,567 shares during the last quarter. Finally, CWM LLC lifted its holdings in MBX Biosciences by 28.9% during the fourth quarter. CWM LLC now owns 1,784 shares of the company’s stock valued at $56,000 after purchasing an additional 400 shares during the last quarter.

MBX Biosciences Stock Performance

Shares of MBX stock traded up $0.01 during trading hours on Friday, reaching $36.85. The company’s stock had a trading volume of 949,864 shares, compared to its average volume of 681,412. MBX Biosciences has a fifty-two week low of $4.81 and a fifty-two week high of $44.89. The company’s 50 day moving average is $33.45.

MBX Biosciences (NASDAQ:MBX – Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.10.

Wall Street Analyst Weigh In

MBX has been the subject of several recent analyst reports. Barclays initiated coverage on MBX Biosciences in a research note on Tuesday. They issued an “overweight” rating and a $66.00 price target for the company. The Goldman Sachs Group assumed coverage on MBX Biosciences in a research report on Thursday, December 4th. They issued a “sell” rating and a $18.00 price objective on the stock. UBS Group began coverage on shares of MBX Biosciences in a research report on Wednesday, January 7th. They set a “buy” rating and a $60.00 target price for the company. Stifel Nicolaus increased their target price on MBX Biosciences from $45.00 to $50.00 and gave the company a “buy” rating in a research report on Friday, December 19th. Finally, Guggenheim lifted their price objective on shares of MBX Biosciences from $77.00 to $88.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Eleven analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, MBX Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $50.20.

View Our Latest Analysis on MBX

About MBX Biosciences

(Get Free Report)

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.

See Also